Phase 3 N=17,535 Clostridium Difficile Vaccine Efficacy Trial
Clostridium Difficile Infection
Primary: Number of First Primary Episodes of Clostridium Difficile Infection (CDI) (Definition 1) Follow-up After Dose 3 — 17; 25 Episodes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=881 Efficacy of a Web-based Sexual Violence Risk Reduction Program for Female College Students
Sexual Violence
Primary: Change From Baseline in Sexual Violence Victimization at 6-months Follow-up — 5.64; 5.68; 5.52; 8.15 score on a scale — p=.0002
N/A N=157 Accelerometer Sensing for Micra AV Study
AV Block · AV Block Complete · 3rd Degree Heart Block
Primary: Atrioventricular (AV) Synchrony During Rest at 1-month Post-implant in Subjects With Persistent 3rd Degree Atrioventrcular Block (AVB) and Normal Sinus Node Function…
N/A N=92 Water Up@ At Home: An Intervention to Replace Sugary Drinks With Water
Diabetes Mellitus, Type 2
Primary: Change in Sugary Drink Consumption for Parents — 12; 14.29; 4.57; 8.57 oz/day — p=0.15
Phase 1 N=14 Comparing Traditional and Biofeedback Telepractice Treatment for Residual Speech Errors
Speech Sound Disorder
Primary: Within-session Change in Percentage of "Correct" Ratings by Blinded Naive Listeners for /r/ Sounds Produced in Word Probes — 1.4; 1.9 Percent correct — p=.72
Phase 2 N=47 Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers
Familial Adenomatous Polyposis
Primary: 13-HODE Colonic Tissue Levels — 14.56; 18.83; 23.02; 20.03 ng/mg tissue protein
Phase 2 N=27 A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris
Pemphigus Vulgaris
Primary: Percentage of Participants With Treatment-emergent Adverse Events — 74.1; 86.7; 11.1; 0 percentage of participants
Phase 3 N=387 Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Agitation in Patients With Dementia of the Alzheimer's Type
Primary: Stage 1 and Stage 2: Change From Baseline in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score to Week 6 and Week 12 — 73.9; 72.3; 71.7; -10.7 units on a…
Phase 2 N=13 A Study for Ureter Visualization, Using ASP5354 in Subjects Undergoing Laparoscopic/Minimally Invasive Colorectal Surgery
Laparoscopic/Minimally Invasive Colorectal Surgery
Primary: Percentage of Participants With Successful Anatomical Visualization of the Index Ureter(s) — 66.7; 100.0; 100.0; 66.7 percentage of participants
Phase 2 N=106 Repeat Quadratus Lumborum Block to Reduce Opioid Need in Patients After Pancreatic Surgery
Pancreatic Carcinoma
Primary: Number of Participants Discharged Opioid-Free — 19; 27 Participants — p=0.17
N/A N=57,581 Lottery Incentive Nudges to Increase Influenza Vaccinations
Influenza · Vaccination · Health Promotion
Primary: Flu Vaccination at Appointment — 10461; 10511; 10394; 10746 Participants — p=.506
Phase 2 N=57 The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
HIV Infections
Primary: Geometric Mean Area Under the Plasma Concentration-time Curve Over 24 Hours (AUC0-24h) for ABC, DTG, and 3TC — 17.7; 19.8; 15.1; 17.4 h*ug/mL
Phase 4 N=123 CESI With Low Dose Lidocaine and Transient Weakness
Cervical Radiculitis · Pain
Primary: Change in Strength in Both Groups After CESI. — 25; 30; 35; 30 Participants — p=.05
N/A N=138 Improving Effective Contraceptive Use Among Opioid-maintained Women: Stage II
Contraceptive Usage · Opioid Dependence
Primary: Percentage of Participants With Verified Prescription Contraceptive Use at the 6-month Assessment — 5; 14; 23 Participants — p=<.001
N/A N=229 Disseminating Public Health Evidence to Support Prevention and Control of Diabetes Among Local Health Departments
Organizational Support for Evidence-based Public Health
Primary: Evidence-based Decision Making (EBDM) Competencies — 2.05; 1.98 score on a scale